Sep 09, 2021 / 03:00PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Thanks for joining us on day 1 of our health care conference. I'm Tejas Savant, and I cover the life science tools and diagnostics sector here at Morgan Stanley. I'm delighted to have Hologic join us today. And representing the company are Steve MacMillan, CEO; and Karleen Oberton, CFO. Welcome to you both.
Before we kick off with the Q&A, just a quick safe harbor here. Please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please do reach out to your sales rep.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystSo Steve, with that, on the -- let's get right to it. On the last earnings call, you provided a long-term organic revenue growth guide of 5% to 7%. Could you walk us through what you view as the key drivers behind that long-term organic growth? And